Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin

Mini-Reviews in Medicinal Chemistry

Volumn 12, Issue 13, 2012, Pages 1345-1358

  Agrawal, Ritesh ^a   Bahare, Radhe Shyam ^b   Jain, Pratima ^a   Dikshit, Subodh Narayan ^a   Ganguly, Swastika ^b  

^a GOVERNMENT SCIENCE COLLEGE   (India)

^b BIRLA INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Alogliptin; Approval; DDP IV; Diabetes Type II; Dipeptidyl Peptidase IV; DPP IV Inhibitor; Emerging Target; GIP; Gliptins; GLP 1; Glucagon like peptide; Incretin; NESINA; Non Insulin Dependent Diabetes Mellitus (NIDDM); SYR 322; Takeda

Indexed keywords

ALOGLIPTIN; ALS 2 0426; ANAGLIPTIN; ARI 2243; CYCLOSPORIN; DA 1229; DB 160; DIGOXIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DSP 7238; EXENDIN 4; GEMIGLIPTIN; GLIBENCLAMIDE; HEMOGLOBIN A1C; KRP 104; LINAGLIPTIN; MELOGLIPTIN; METFORMIN; ONGYLZA; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TENELIGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; COMPUTER ANALYSIS; CONSTIPATION; CRYSTAL STRUCTURE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN TOXICITY; VOMITING;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; MODELS, MOLECULAR; PIPERIDINES; URACIL;

EID: 84870228167     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575112091345     Document Type: Review

References (59)

1. Fact sheet No 138: Diabetes Mellitus-Reviewed November 1999 (WHO, 1999, 3 p.). http://www.nzdl.org/gsdlmod?e=d-00000-00-off-0cdl-00-0-0-10-0-0-0direct-10-4-0-0l-11-en-50-20-about-00-0-1-00-0-0-11-1-0utfZz-8-00&cl=CL3.2.13&d= HASHe0fbd39644189200024211.1&x=1 (Accessed Jan 15, 2011).
2. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27 (5), 1047-1053.
3. Dipeptidyl Peptidase IV. http://www.sigmaaldrich.com/lifescience/metabolomics/enzyme-explorer/cell-signalingenzymes/dipeptidyl-peptidase-iv.html (Accessed Mar 23, 2012).
4. Chehade, J. M.; Mooradian, A. D. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000, 60 (1), 95-113.
5. DeFronzo, R. A. Pathogenesis of type 2 diabetes mellitus. Med. Clin. North Am. 2004, 88 (4), 787-835, ix.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998, 352 (9131), 837-853.
7. Stratton, I. M.; Adler, A. I.; Neil, H. A.; Matthews, D. R.; Manley, S. E.; Cull, C. A.; Hadden, D.; Turner, R. C.; Holman, R. R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000, 321 (7258), 405-412.
8. Kawashima, S.; Matsuoka, T. A.; Kaneto, H.; Tochino, Y.; Kato, K.; Yamamoto, K.; Yamamoto, T.; Matsuhisa, M.; Shimomura, I. Effect of Alogliptin, Pioglitazone and Glargine on Pancreatic Beta-Cells in Diabetic Db/Db Mice. Biochem. Biophys. Res. Commun. 2011, 404, 534-540.
9. Andukuri, R.; Drincic, A.; Rendell, M. Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes Metab Syndr. Obes. 2009, 2:117-26., 117-126.
10. Kutoh, E.; Ukai, Y. Alogliptin as an initial therapy in patients with newly diagnosed, drug naive type 2 diabetes: a randomized, control trial. Endocrine. 2012.
11. Agrawal, R.; Jain, P.; Dikshit, S. N. Linagliptin: A Novel Methylxanthines Based Approved Dipeptidyl Peptidase-4 Inhibitor. Curr. Drug Targets. 2012.
12. Alogliptin. http://en.wikipedia.org/wiki/Alogliptin (Accessed May 23, 2011).
13. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 2007, 50 (10), 2297-2300.
14. Schechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27 (2), 157-162.
15. Magnin, D. R.; Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L. M.; Taunk, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.; Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han, S. P.; Parker, R. A.; Hamann, L. G. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors. J. Med. Chem. 2004, 47 (10), 2587-2598.
16. Lambeir, A. M.; Proost, P.; Durinx, C.; Bal, G.; Senten, K.; Augustyns, K.; Scharpe, S.; Van, D. J.; De, M., I Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J. Biol. Chem. 2001, 276 (32), 29839-29845.
17. Thornberry, N. A.; Gallwitz, B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best. Pract. Res. Clin. Endocrinol. Metab 2009, 23 (4), 479-486.
18. Deacon, C. F.; Carr, R. D.; Holst, J. J. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Front Biosci. 2008, 13, 1780-1794.
19. Baggio, L. L.; Drucker, D. J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132 (6), 2131-2157.
20. Holst, J. J.; Vilsboll, T.; Deacon, C. F. The incretin system and its role in type 2 diabetes mellitus. Mol. Cell Endocrinol. 2009, 297 (1-2), 127-136.
21. Halimi, S. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients? Diabetes Metab., 2009, 34, S91-95.
22. Abbatecola, A. M.; Maggi, S.; Paolisso, G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging 2008, 25 (11), 913-925.
23. Aytac, U.; Dang, N. H. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 2004, 4 (1), 11-18.
24. Koliaki, C.; Doupis, J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus. Diabetes Ther. 2011, 2 (2), 101-121.
25. Alogliptin benzoate. www.lookchem.com/Alogliptin-benzoate/(Accessed May 23, 2011).
26. United States Patent and Trademark Office. http://www.uspto.gov/(Accessed Mar 23, 2011).
27. European Patent Office. http://ep.espacenet.com (Accessed Feb 02, 2011).
28. WIPO-World Intellectual Property Organization. http://www.wipo.int/pctdb/en/search-adv.jsp (Accessed Feb 02, 2011).
29. Mark, A.; Keith, L. Polymorphs of benzoate salt of 2-[6-[(3r)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl]methyl]-benzonitrile and methods of use thereof. US20070066635, Sep 13, 2006. 2011.
30. Zhiyuan, Z.; Bruce J., Elder; P. K., Isbester, G. J.; Palmer, L. G.; U. Dipeptidyl peptidase inhibitors. US7807689, October 5, 2010. 2011.
31. Nesina® (Alogliptin). http://www.furiex.com/pipeline/alogliptin/(Accessed Sep 23, 2011).
32. Thareja, S.; Aggarwal, S.; Malla, P.; Haksar, D.; Bhardwaj, T. R.; Kumar, M. Saxagliptin: a new drug for the treatment of type 2 diabetes. Mini. Rev. Med. Chem. 2010, 10 (8), 759-765.
33. www.rcsb.org, PDB ID: 2ONC. Feng, J.; Zhang, Z.; Wallace, M. B.; Stafford, J. A.; Kaldor, S. W.; Kassel, D. B.; Navre, M.; Shi, L.; Skene, R. J.; Asakawa, T.; Takeuchi, K.; Xu, R.; Webb, D. R.; Gwaltney, S. L. Discovery of Alogliptin: a Potent, Selective, Bioavailable, and Efficacious Inhibitor of Dipeptidyl Peptidase IV. J. Med. Chem. 2008, 51, 4357-4358.
34. PoseView is available as standalone tool and integrated in the LeadIT platform at http://www.biosolveit.de/poseview (Accessed Mar 20, 2012).
35. Chien, C. H.; Huang, L. H., Chou, C. Y. Investigation of the Dimer Interface and Substrate Specificity of Prolyl Dipeptidase DPP8J. Biol. Chem, 2004, 279, 52338-52345.
36. Fulop, V.; Jones, D. T. Beta propellers: structural rigidity and functional diversity. Curr Opin Struct Biol Struct. Biol., 1999, 9, 715-721.
37. Chien, C. H.; Huang, L. H.; Chou, C. Y.; Chen, Y. S.; Han, Y. S.; Chang, G. G.; Liang, P. H.; Chen, X. One site mutation disrupts dimer formation in human DPP-IV proteins. J. Biol. Chem., 2004, 279 (50), 52338-52345.
38. Karim, A.; Chiselko, P.; Fleck, P.; Harris, S.; Munsaka, M.; Mekki, Q. Lack of effect of cyclosporine on the single dose pharmacokinetics of Alogliptin, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Clin. Pharmacol. Ther. 2008, 83, Abstract Suppl. 1:S13.
39. Covington, P.; Christopher, R.; Davenport, M.; Fleck, P.; Mekki, Q. A.; Wann, E.R.; Karim, A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 2008, 30 (3), 499-512.
40. Covington, P.; Christopher, R.; Davenport, M. Lack of pharmacokinetic interaction between Alogliptin benzoate (SYR-322) and metformin in healthy subjects. Diabetes. 2007, 56 abstract (suppl. 1): A541-A542. 2011.
41. Karim, A.; Copa, A.; Fleck, P.; Helland, J.; Munsaka, M.; Mekki, Q. Effects of Alogliptin on the pharmacokinetics and pharmacodynamics of norethindrone and ethinyl estradiol (ORTHO-NOVUM(R) 1/35) in healthy adult female subjects. Clin. Pharmacol. Ther., 2008, 83, Abstract Suppl. S13.
42. Alan, J.G.; Stephen, J.S. An overview of incretin clinical trials, The Journal of Family Practice, 2008, 57(9), Suppl. S10-S18. 2011.
43. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Lerch, C. Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of T2DM. Vasc. Health Risk Manag. 2008, 4, 753-768.
44. Rosenstock, J.; Sankoh, S.; List, J. F. Glucose-Lowering Activity of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin in Drug-Naive Patients With T2DM. Diabetes Obes. Metab., 2008, 10, 376-386.
45. DeFronzo, R. A.; Hissa, M. N.; Garber, A. J.; Luiz, G. J.; Yuyan, D. R.; Ravichandran, S.; Chen, R. S. The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled T2DM With Metformin Alone. Diabetes Care, 2009, 32, 1649-1655.
46. Hayat, S:, Atif, S.; Naila, Ali.; Pyar, S. Z:. Tariq, K. Haque, A. Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus, World Applied Sci. J., 2009, 7 (1), 01-06.
47. Thareja, S.; Aggarwal, S.; Malla, P.; Haksar, D.; Bhardwaj, T. R.; Kumar, M. Saxagliptin: a New Drug for the Treatment of T2DM. Mini. Rev. Med. Chem., 2010, 10, 759-765.
48. Asakawa, T.; Moritoh, Y.; Kataoka, O.; Suzuki, N.; Takeuchi, K.; Odaka, H. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci., 2009, 85 (3-4), 122-126.
49. Christopher, R.; Covington, P.; Davenport, M.; Fleck, P.; Mekki, Q. A.; Wann, E. R.; Karim, A. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single Increasing Doses of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Healthy Male Subjects. Clin. Ther., 2008, 30, 513-527.
50. Covington, P.; Christopher, R.; Davenport, M. et al. Lack of pharmacokinetic interaction between alogliptin benzoate (SYR-322) and metformin in healthy subjects. Presented at: 67th Scientific Sessions of the American Diabetes Association; June 22-26, 2007, Chicago, Ill, 2011.
51. Karim A, Fleck P, Harris S, et al. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Clin Pharmacol Ther. 2008;83(Suppl 1): abstract PI-13. http://www.nature.com/clpt/journal/v83/n1s/pdf/clpt200838a.pdf. Accessed March 25, 2010. 2011.
52. Neumiller, J. J. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment. Clin. Ther. 2011, 33 (5), 528-576.
53. Pratley, R. E.; Reusch, J. E.; Fleck, P. R.; Wilson, C. A.; Mekki, Q. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin Added to Pioglitazone in Patients With T2DM: a Randomized, Double-Blind, Placebo-Controlled Study. Curr. Med. Res. Opin. 2009, 25, 2361-2371.
54. Pratley, R. E.; Kipnes, M. S.; Fleck, P. R.; Wilson, C.; Mekki, Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes. Metab., 2009, 11 (2), 167-176.
55. Nauck, M. A.; Ellis, G. C.; Fleck, P. R.; Wilson, C. A.; Mekki, Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int. J. Clin. Pract., 2009, 63 (1), 46-55.
56. Pratley, R. E.; McCall, T.; Fleck, P. R.; Wilson, C. A.; Mekki, Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J. Am. Geriatr. Soc., 2009, 57 (11), 2011-2019.
57. Triplitt, C.; Cersosimo, E.; DeFronzo, R. A. Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment. Vasc. Health Risk Manag., 2010, 6, 671-690.
58. Inzucchi, S. E.; Rosenstock, J.; Seufert, J.; Fleck, P.; Wilson, C.; Mekki, Q. Effect of combination therapy with Alogliptin and pioglitazone in drug-naïve patients with T2DM on b-cell function and insulin resistance. Diabetes, 2009, 58, (1:A520), 2026.
59. Fact sheet No 138: Diabetes Mellitus-Reviewed November 1999 (WHO, 1999, 3 p.). http://www.nzdl.org/gsdlmod?e=d-00000-00-off-0cdl-00-0-0-10-0-0-0direct-10-4